Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 5 Most Undervalued Companies for the Defensive Investor – February 2015. By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a specific look at how Edwards Lifesciences Corporation (EW) fares in the ModernGraham valuation model.
Company Profile (obtained from Google Finance): Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Cardiovascular disease is the primary cause of death in the world, and is the top disease in terms of health care spending in nearly every country. Cardiovascular disease is progressive in that it tends to worsen over time and often affects an individual’s entire circulatory system. The products and technologies provided by Edwards Lifesciences are categorized as Surgical Heart Valve Therapy, combining surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care.
Defensive Investor – must pass at least 6 of the following 7 tests: Score = 4/7
- Adequate Size of Enterprise – market capitalization of at least $2 billion -Â PASS
- Sufficiently Strong Financial Condition – current ratio greater than 2 -Â PASS
- Earnings Stability – positive earnings per share for at least 10 straight years -Â PASS
- Dividend Record – has paid a dividend for at least 10 straight years -Â FAIL
- Earnings Growth – earnings per share has increased by at least 1/3 over the last 10 years using 3 year averages at beginning and end of period -Â PASS
- Moderate PEmg ratio – PEmg is less than 20 -Â FAIL
- Moderate Price to Assets – PB ratio is less than 2.5 or PB x PEmg is less than 50 -Â FAIL
Enterprising Investor – must pass at least 4 of the following 5 tests or be suitable for a defensive investor: Score = 4/5
- Sufficiently Strong Financial Condition, Part 1 – current ratio greater than 1.5 -Â PASS
- Sufficiently Strong Financial Condition, Part 2 – Debt to Net Current Assets ratio less than 1.1 -Â PASS
- Earnings Stability – positive earnings per share for at least 5 years – PASS
- Dividend Record – currently pays a dividend -Â FAIL
- Earnings growth – EPSmg greater than 5 years ago -Â PASS
Valuation Summary
Key Data:
| Recent Price | $133.90 |
| MG Value | $165.06 |
| MG Opinion | Fairly Valued |
| Value Based on 3% Growth | $62.17 |
| Value Based on 0% Growth | $36.44 |
| Market Implied Growth Rate | 11.37% |
| Net Current Asset Value (NCAV) | $8.77 |
| PEmg | 31.23 |
| Current Ratio | 5.29 |
| PB Ratio | 6.70 |
Balance Sheet – December 2014
| Current Assets | $2,295,000,000 |
| Current Liabilities | $434,000,000 |
| Total Debt | $598,000,000 |
| Total Assets | $3,524,000,000 |
| Intangible Assets | $399,000,000 |
| Total Liabilities | $1,333,000,000 |
| Outstanding Shares | 109,700,000 |
Earnings Per Share
| 2014 | $7.48 |
| 2013 | $3.42 |
| 2012 | $2.48 |
| 2011 | $1.98 |
| 2010 | $1.83 |
| 2009 | $1.95 |
| 2008 | $1.10 |
| 2007 | $0.94 |
| 2006 | $1.05 |
| 2005 | $0.64 |
| 2004 | $0.02 |
Earnings Per Share – ModernGraham
| 2014 | $4.29 |
| 2013 | $2.57 |
| 2012 | $2.05 |
| 2011 | $1.75 |
| 2010 | $1.55 |
| 2009 | $1.31 |
Dividend History
Edwards Lifesciences Corp does not pay a dividend.
Conclusion:
Edwards Lifesciences Corporation is suitable for the Enterprising Investor but not for the Defensive Investor.  The Defensive Investor is concerned by the lack of dividend payments, and the high PEmg and PB ratios. The Enterprising Investor is only concerned by the lack of dividends.  As a result, Enterprising Investors following the ModernGraham approach based on Benjamin Graham’s methods should feel very comfortable proceeding with further research and comparing the company to other opportunities.  From a valuation side of things, the company appears to be fairly valued after growing its EPSmg (normalized earnings) from $1.55 in 2010 to $4.29 for 2014.  This level of demonstrated growth supports the market’s implied estimate of 11.37% earnings growth and leads the ModernGraham valuation model, based on Benjamin Graham’s formula, to return an estimate of intrinsic value within a margin of safety relative to the price.
Be sure to check out previous ModernGraham valuations of Edwards Lifesciences Corporation (EW)Â for greater perspective!
The next part of the analysis is up to individual investors, and requires discussion of the company’s prospects.  What do you think?  What value would you put on Edwards Lifesciences Corporation (EW)?  Where do you see the company going in the future?  Is there a company you like better?  Leave a comment on our Facebook page or mention @ModernGraham on Twitter to discuss.
Disclaimer:  The author did not hold a position in Edwards Lifesciences Corporation (EW) or in any other company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  Logo taken from Wikipedia for the sole purpose of identifying the company; this article is not affiliated with the company in any manner.
Leave a Reply